Although India’s pharmaceutical exports to the US remain exempt from the recently announced 50 percent tariffs, several Indian life sciences companies are investing in establishing manufacturing facilities in the United States to strengthen supply chain resilience, meet regulatory requirements, and mitigate future trade risks. This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — inaugurated major facilities in New Jersey, underscoring a growing trend of overseas investment by Indian pharma companies.

On September 3, Enzene, a leading global continuously innovative development and manufacturing organisation (CIDMO), inaugurated a USD 50 million biomanufacturing facility in Hopewell, New Jersey — its first major US investment. The 80,000-square-foot site includes 26,000 square feet of drug substance manufacturing suites, labs, storage, and warehousing. In addition to fed-batch drug substance manufacturing, the site features the company’s EnzeneX 2.0 platform, the world’s first fully-connected continuous manufacturing (FCCM) technology.

Enzene CEO Himanshu Gadgil said the new site will operate in tandem with its Indian facilities to deliver global supply solutions.

“Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high-yield, US-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions,” he said.

On September 4, Aurobindo Pharma USA officially opened a 170,000-square-foot warehouse in East Windsor, expanding its North American headquarters campus. The new facility strengthens the company’s integrated operations — spanning manufacturing, packaging, and shipping.

On September 11, Biocon Generics Inc. (BGI), a wholly owned subsidiary of Biocon, inaugurated its first US manufacturing plant in Cranbury, New Jersey. Biocon acquired the site from Eywa Pharma in 2023 and has since invested more than USD 30 million to establish a state-of-the-art Oral Solid Dosage (OSD) facility with a production capacity of two billion tablets annually. Some products have already been commercialised, with more in the pipeline.

Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “Biocon’s first US FDA approved formulations facility in New Jersey marks a new chapter in our journey of global expansion.”

Together, these investments highlight how Indian pharmaceutical companies are strengthening their US presence by building local capacity, diversifying supply chains, and accelerating their global growth strategies.